Hi Mason,
If we look at the announcement & the presentation from an agnostic point of view & focus on the facts.
PTX-100 had an excellent safety profile across the entire cohort. Considering safety was the primary focus of the study I think we can all agree ptx-100 performed as well as it possibly could .
As for efficacy, we know that 2/2 patients in the cohort had a response to ptx-100. It sounds like there were other responses from the mixed cohort however we will leave that at the door.
The 1B basket case study has helped management & Professor Miles of the Epworth/Peter Mac identify TCL cancer as the optimal target market to progress with in the expanded cohort.
That's about the crux of it, as a shareholder I think the report was positive reading and there is very good reason for optimism regarding the expanded cohort targeting TCL cancer.
The ptx-100 expanded cohort study results will be a very critical juncture for 'Prescient Therapeutics', company making if we can build on or replicate the initial TCL response from the initial mixed basket cohort study.
Will be very interesting to see what data is derived from the study in due time.
- Forums
- ASX - By Stock
- PTX
- Ann: PTX-100 trial advances following successful Phase 1b
Ann: PTX-100 trial advances following successful Phase 1b, page-276
-
- There are more pages in this discussion • 131 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.2¢ |
Change
-0.001(2.33%) |
Mkt cap ! $33.82M |
Open | High | Low | Value | Volume |
4.4¢ | 4.4¢ | 4.2¢ | $8.186K | 192.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 32689 | 4.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.3¢ | 5704 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 32689 | 0.042 |
1 | 490222 | 0.041 |
9 | 797493 | 0.040 |
6 | 539000 | 0.039 |
3 | 375000 | 0.038 |
Price($) | Vol. | No. |
---|---|---|
0.043 | 5704 | 1 |
0.044 | 225514 | 2 |
0.045 | 845136 | 7 |
0.047 | 525000 | 2 |
0.048 | 308027 | 2 |
Last trade - 12.13pm 15/08/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online